NCT06887348View on ClinicalTrials.gov

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2035

Conditions
MelanomaMetastatic MelanomaAdvanced Solid TumorHepatocellular Carcinoma
Interventions
OTHER

Observational study with no interventions

This is an observational study and there will be no clinical interventions.

All Listed Sponsors
lead

Replimune Inc.

INDUSTRY

NCT06887348 - A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 | Biotech Hunter | Biotech Hunter